01652.HK
Fusen Pharmaceutical Company Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 1.03
+3.00%Year over year
Reported trailing growth
- Revenue
- +14.6%
- EBITDA
- +665.7%
- EBIT
- +126.0%
- EPS
- +98.6%
- Free cash flow
- -69.7%
- Operating cash flow
- -49.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -17.8%
- EBITDA
- -38.6%
- EBIT
- +97.5%
- Net income
- +93.8%
- EPS
- +93.9%
- Free cash flow
- -6.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026